Evidence map›Paper›PMID 30023805›Full record

ArticleACS omega2018

Engineering of a New Bisphosphonate Monomer and Nanoparticles of Narrow Size Distribution for Antibacterial Applications.

Nimrod Tal, Safra Rudnick-Glick, Igor Grinberg, Michal Natan, Ehud Banin, Shlomo Margel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nimrod TalThe Institute of Nanotechnology and Advanced Materials, Department of Chemistry, and The Mina and Everard Goodman Faculty of Life Sciences, The Institute for Advanced Materials and Nanotechnology, Bar-Ilan University, Ramat-Gan 52900, Israel.
Safra Rudnick-GlickThe Institute of Nanotechnology and Advanced Materials, Department of Chemistry, and The Mina and Everard Goodman Faculty of Life Sciences, The Institute for Advanced Materials and Nanotechnology, Bar-Ilan University, Ramat-Gan 52900, Israel.
Igor GrinbergThe Institute of Nanotechnology and Advanced Materials, Department of Chemistry, and The Mina and Everard Goodman Faculty of Life Sciences, The Institute for Advanced Materials and Nanotechnology, Bar-Ilan University, Ramat-Gan 52900, Israel.
Michal NatanThe Institute of Nanotechnology and Advanced Materials, Department of Chemistry, and The Mina and Everard Goodman Faculty of Life Sciences, The Institute for Advanced Materials and Nanotechnology, Bar-Ilan University, Ramat-Gan 52900, Israel.
Ehud BaninThe Institute of Nanotechnology and Advanced Materials, Department of Chemistry, and The Mina and Everard Goodman Faculty of Life Sciences, The Institute for Advanced Materials and Nanotechnology, Bar-Ilan University, Ramat-Gan 52900, Israel.
Shlomo MargelThe Institute of Nanotechnology and Advanced Materials, Department of Chemistry, and The Mina and Everard Goodman Faculty of Life Sciences, The Institute for Advanced Materials and Nanotechnology, Bar-Ilan University, Ramat-Gan 52900, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, many bacteria have developed resistance to commonly used antibiotics. It is well-known that calcium is essential for bacterial function and cell wall stability. Bisphosphonates (BPs) have high affinity to calcium ions and are effective calcium chelators. Therefore, BPs could potentially be used as antibacterial agents. This article provides a detailed description regarding the synthesis of a unique BP vinylic monomer MA-Glu-BP (methacrylate glutamate bisphosphonate) and polyMA-Glu-BP nanoparticles (NPs) for antibacterial applications. polyMA-Glu-BP NPs were synthesized by dispersion copolymerization of the MA-Glu-BP monomer with the primary amino monomer

Identifiers

PMID30023805
PMCPMC6044825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.